Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision cancer medicines, has announced inducement grants to eight new employees. The Compensation Committee approved nonstatutory stock options to purchase 141,750 shares of common stock under the company's 2023 Inducement Option Plan.
The stock options have an exercise price of $5.60 per share, based on the closing price on July 1, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.
Kura Oncology (Nasdaq: KURA), una società biofarmaceutica in fase clinica specializzata in farmaci oncologici di precisione, ha annunciato concessioni di incentivi a otto nuovi dipendenti. Il Comitato per la Retribuzione ha approvato opzioni azionarie non statutarie per l'acquisto di 141.750 azioni ordinarie nell'ambito del Piano Opzioni Incentivo 2023 della società.
Le opzioni azionarie hanno un prezzo di esercizio di 5,60 $ per azione, basato sul prezzo di chiusura del 1° luglio 2025. Le opzioni matureranno in quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente nei successivi 36 mesi, subordinatamente al mantenimento dell'impiego.
Kura Oncology (Nasdaq: KURA), una empresa biofarmacéutica en etapa clínica centrada en medicamentos oncológicos de precisión, ha anunciado concesiones de incentivos a ocho nuevos empleados. El Comité de Compensación aprobó opciones sobre acciones no estatutarias para comprar 141,750 acciones ordinarias bajo el Plan de Opciones de Incentivo 2023 de la compañía.
Las opciones sobre acciones tienen un precio de ejercicio de $5.60 por acción, basado en el precio de cierre del 1 de julio de 2025. Las opciones se consolidarán en un período de cuatro años, con un 25% consolidado después de un año y el resto consolidándose mensualmente durante los siguientes 36 meses, condicionado a la continuidad del empleo.
Kura Oncology (나스닥: KURA)는 정밀 암 치료제에 중점을 둔 임상 단계 바이오제약 회사로서, 8명의 신입 직원에게 유인 주식을 부여했다고 발표했습니다. 보상 위원회는 회사의 2023년 유인 옵션 계획에 따라 141,750주의 보통주를 매수할 수 있는 비법정 주식 옵션을 승인했습니다.
주식 옵션의 행사가격은 2025년 7월 1일 종가 기준 주당 5.60달러입니다. 옵션은 4년에 걸쳐 권리가 부여되며, 1년 후 25%가 부여되고 나머지는 36개월 동안 매월 부여되며, 계속 고용 상태인 경우에 한합니다.
Kura Oncology (Nasdaq : KURA), une société biopharmaceutique en phase clinique spécialisée dans les médicaments oncologiques de précision, a annoncé des attributions d'incitations à huit nouveaux employés. Le comité de rémunération a approuvé des options d'achat d'actions non statutaires pour acquérir 141 750 actions ordinaires dans le cadre du Plan d'options d'incitation 2023 de la société.
Le prix d'exercice des options est de 5,60 $ par action, basé sur le cours de clôture du 1er juillet 2025. Les options seront acquises sur une période de quatre ans, avec 25 % acquis après un an et le reste acquis mensuellement sur 36 mois, sous réserve de la poursuite de l'emploi.
Kura Oncology (Nasdaq: KURA), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Fokus auf präzisionsmedizinische Krebsbehandlungen, hat Zuteilungen von Anreizen an acht neue Mitarbeiter angekündigt. Der Vergütungsausschuss genehmigte nichtstatutarische Aktienoptionen zum Kauf von 141.750 Aktien des Stammkapitals im Rahmen des Inducement-Optionsplans 2023 des Unternehmens.
Die Aktienoptionen haben einen Ausübungspreis von 5,60 $ pro Aktie, basierend auf dem Schlusskurs vom 1. Juli 2025. Die Optionen werden über vier Jahre erworben, wobei 25 % nach einem Jahr und der Rest monatlich über 36 Monate erworben werden, vorbehaltlich einer fortgesetzten Anstellung.
- None.
- None.
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 141,750 shares of common stock to eight (8) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors:
Patti Bank
Managing Director
(415) 513-1284
patti.bank@icrhealthcare.com
Media:
media@kuraoncology.com
FAQ
What inducement grants did Kura Oncology (KURA) announce on July 3, 2025?
What is the vesting schedule for Kura Oncology's (KURA) new stock options?
What is the exercise price for KURA's July 2025 inducement stock options?
How many new employees received stock options from Kura Oncology in July 2025?
